All lobbying filings

Apotex Corp.

Apotex Corp. filed a Q3 report for Apotex Corp. on October 19, 2026.

Lobbying for Apotex Corp.

As filed: APOTEX CORP. for APOTEX CORP.

All filings by Apotex Corp. · Everything Apotex Corp. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Expenses

$220,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Florida

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Manufacturing

Federal policy relating to providing federal funding to strengthen capabilities for domestic manufacturing of generic drugs and their ingredients; and Federal policy relating to amending Hatch-Waxman Act 180-day NCE-1 exclusivity eligibility to provide incentives for manufacturing generic pharmaceuticals and their ingredients in the United States and allied nations.

Trade (domestic/foreign)

Federal policy relating to the review of the United States-Mexico-Canada trade agreement and the North American generic drug supply chain.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.